Efficacy and safety of recombinant human thrombomodulin for the patients with coagulopathy before cardiovascular surgery

Efficacy and safety of recombinant human thrombomodulin for the patients with coagulopathy before cardiovascular surgery - Efficacy and safety of recombinant human thrombomodulin for DIC patients before cardiovascular surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010632

Enrollment

Registered

2013-05-01

Start date

2013-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic aneurysm

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients showing intracranial, pulmonary or gastrointestinal hemorrhage. 2) Patients with serious hepatopathy such as fulminant hepatitis, uncompensated liver cirrhosis and others 3) Patients with a history of hypersensitivity to rTM. 4) Pregnant women, nursing mothers or possibly pregnant women.

Exclusion criteria

Exclusion criteria: 1) Patients showing intracranial, pulmonary or gastrointestinal hemorrhage. 2) Patients with serious hepatopathy such as fulminant hepatitis, uncompensated liver cirrhosis and others 3) Patients with a history of hypersensitivity to rTM. 4) Pregnant women, nursing mothers or possibly pregnant women.

Design outcomes

Primary

Measure	Time frame
DIC score (at the day-6 after the commence of the treatment)	—

Secondary

Measure	Time frame
Blood clotting test findings (FDP, Ddimer, TAT, PIC) AT activity CRP	—

Countries

Japan

Contacts

Public ContactTomonori Shirasaka

Kobe University Graduate School of Medicine, Kobe, Japan Department of Surgery, Division of Cardiovascular Surgery

Outcome results